The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC).
B. Besse
Consultant or Advisory Role - Roche (U)
Research Funding - Roche
J. Soria
Honoraria - Genentech
C. Gomez-Roca
No relevant relationships to disclose
J. A. Ware
Employment or Leadership Position - Genentech
Stock Ownership - Roche
A. A. Adjei
No relevant relationships to disclose
G. K. Dy
No relevant relationships to disclose
G. Shankar
Employment or Leadership Position - Genentech
Stock Ownership - Roche
R. K. Brachmann
Employment or Leadership Position - Genentech
Stock Ownership - Roche
H. J. Groen
Consultant or Advisory Role - Lilly (U); Roche (U)
Research Funding - Pfizer